MUSE Cell (Multilineage-differentiating Stress Enduring) Therapy — Regenerative Therapies
Naturally occurring pluripotent-like cells identified by SSEA-3 expression, stress-resistant with non-tumorigenic profile. Japan-led clinical development.
Overview
MUSE (Multilineage-differentiating Stress Enduring) cells are a distinct subpopulation of mesenchymal stromal cells identified by SSEA-3 expression. Discovered by Mari Dezawa at Tohoku University (Japan) in 2010, MUSE cells represent 1-3% of bone marrow MSCs and possess unique properties: naturally pluripotent-like (differentiate into all three germ layers), stress-resistant (survive severe conditions), non-tumorigenic (do not form teratomas - critical safety advantage over iPSCs/ESCs), and exhibit selective homing to damaged tissue via S1P-S1PR2 axis. CL2020 (Mitsubishi Tanabe Pharma/Life Science Institute) is the lead clinical product. Clinical trials in Japan have investigated MUSE cells for acute myocardial infarction (COSMI trial), ischemic stroke, epidermolysis bullosa, spinal cord injury, and neonatal hypoxic-ischemic encephalopathy. Early results showed safety and preliminary efficacy signals, though the 2023 Phase 3 AMI trial did not meet its primary endpoint.
Indications
- Acute myocardial infarction (COSMI trial - Japan)
- Ischemic stroke (subacute phase)
- Epidermolysis bullosa (dystrophic and junctional)
- Spinal cord injury (subacute)
- Neonatal hypoxic-ischemic encephalopathy
- Acute respiratory distress syndrome (ARDS)
Mechanism of Action
SSEA-3+ cells isolated from bone marrow MSCs or adipose tissue (1-3% of MSC population). Can be enriched by severe stress application which selectively kills non-MUSE cells
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| CL2020 (Allogeneic MUSE Cells) | 1.5 x 10^7 cells (15 million) | Single infusion within 2 weeks of MI | IV infusion for acute MI (COSMI Phase 2 trial) |
| CL2020 (Allogeneic MUSE Cells) | 1.5 x 10^7 cells (15 million) | Single infusion within 4 weeks of stroke | IV infusion for ischemic stroke |
Evidence Grade
GRADE C
Safety & Contraindications
- Not FDA-approved - clinical development primarily in Japan
- Phase 3 AMI trial (2023) did not meet primary endpoint - efficacy uncertain
- Non-tumorigenic profile is a significant safety advantage over iPSCs/ESCs
- Allogeneic use (CL2020) does not require immunosuppression - immune-privileged
- Limited clinical data globally - fewer than 200 patients treated
- Donor-to-donor variability in MUSE cell content and potency
- SSEA-3+ cell isolation adds manufacturing complexity
- Long-term safety beyond 2-3 years not established
- IV administration: theoretical risk of pulmonary first-pass trapping